Julian Kaye

Treating estrogen receptor–positive breast cancer without sparking resistance is a complex endeavor that should involve simultaneously targeting the hormone-signaling and PI3 kinase molecular pathways

Despite the trend toward targeted therapies, cytotoxic drugs remain a mainstay of metastatic breast cancer treatment, and new therapies in that class are needed.

An overview of studies looking at the potential of osteoclast inhibitors in the prevention of breast cancer recurrences in the adjuvant setting.